drugset / Trial / NCT00292721

Effects of Celecoxib After Percutaneous Coronary Intervention

NCT00292721

Phase 4 Completed 260 enrolled Seoul National University Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Several studies including ours have reported that celecoxib improves endothelium-dependent vasodilation and reduces inflammation and neointimal hyperplasia. Our hypothesis is that celecoxib may reduce the late luminal loss after coronary stent implantation (paclitaxel-eluting stent.

Timeline

Start
2004-08
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Celecoxib Other / unclassified 200 mg